Part the Cloud: Phase 1 and Phase 2 Clinical Studies — 2027 Funding

Supports translational studies of potential Alzheimer’s and related-dementia therapies, including early human safety, target engagement and proof of mechanism. Awards provide up to USD 1 million over two to three years; selected Phase 3 or biomarker-validation proposals can also qualify. Letters of intent are due 20 October 2026 at 17:00 Eastern time (22 October for ISTAART members); invited full applications follow on 15 December (17 December for members).

Full-time investigators at Assistant Professor level or equivalent and above; students and postdocs cannot be lead applicants. Eligible international institutions may apply, subject to programme and sanctions rules. Only one proposal per applicant across the current competition; reporting and institutional exclusions apply.